IMG-004 demonstrated extended half-life and durable pharmacodynamic characteristics in a Phase 1 study
Article Date
April 28, 2023
This article is featured on another website.
Go to article
July 8, 2025
Myrtelle Launches Commercial Manufacturing First-in-Class Gene Therapy
Myrtelle Launches Commercial-Stage Manufacturing of First-in-Class Gene Therapy for Canavan Disease.
July 8, 2025
Myrtelle Launches Commercial Manufacturing First-in-Class Gene Therapy
Myrtelle Launches Commercial-Stage Manufacturing of First-in-Class Gene Therapy for Canavan Disease.
September 16, 2025
Mytrelle Announces Nature Medicine Publication of Interim Results
Myrtelle Announces Nature Medicine Publication of Interim Results from Its Phase 1/2 Clinical Trial of Investigational Gene Therapy rAAV-Olig001-ASPA for Canavan Disease
September 16, 2025
Mytrelle Announces Nature Medicine Publication of Interim Results
Myrtelle Announces Nature Medicine Publication of Interim Results from Its Phase 1/2 Clinical Trial of Investigational Gene Therapy rAAV-Olig001-ASPA for Canavan Disease